Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis: therapeutic update.

A C Tselis1, R P Lisak

  • 1Department of Neurology, Wayne State University School of Medicine, Detroit Medical Center, Mich, USA. atselis@med.wayne.edu

Archives of Neurology
|April 6, 1999
PubMed
Summary

Recent advancements offer new therapeutic options for multiple sclerosis (MS), a disabling immune-mediated central nervous system disease. This review covers current successes, failures, and emerging treatments for MS management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunologic characterization of oligodendroglia.

Neuroscience letters·2009
Same author

Predictors of well-being among significant others of persons with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2007
Same author

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.

Multiple sclerosis (Houndmills, Basingstoke, England)·2006
Same author

Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures.

Multiple sclerosis (Houndmills, Basingstoke, England)·2006
Same author

Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.

Acta neurologica Scandinavica·2004
Same author

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2003

Area of Science:

  • Neurology
  • Immunology
  • Neuroscience

Background:

  • Multiple sclerosis (MS) is a prevalent, disabling neurologic disease affecting young adults.
  • It is characterized by immune-mediated inflammation and demyelination in the central nervous system, with axonal damage.
  • Despite extensive research into pathogenesis, a definitive cure for MS remains elusive, necessitating long-term management.

Purpose of the Study:

  • To review recent therapeutic developments in multiple sclerosis (MS).
  • To discuss both successful and unsuccessful treatment strategies.
  • To explore novel and emerging approaches for MS therapy.

Main Methods:

  • Literature review of recent advancements in multiple sclerosis (MS) therapy.
  • Analysis of clinical trial outcomes and published research.
  • Synthesis of information on current and future treatment strategies.

Main Results:

  • Significant progress has been made in the treatment of multiple sclerosis (MS).
  • Several new therapies have emerged, offering improved management options.
  • Some therapeutic approaches have faced challenges or failures, highlighting the complexity of MS treatment.

Conclusions:

  • The landscape of multiple sclerosis (MS) therapy is rapidly evolving.
  • Recent advances provide hope for improved patient outcomes.
  • Continued research into novel approaches is crucial for addressing the unmet needs in MS management.

Related Experiment Videos